Chamber and committees

Breathing Space is operated by NHS24 to provide free and confidential support for people experiencing low mood, depression and anxiety. The phone line operates between 6pm-2am on weekday evenings and from 6pm Friday to 6am Monday. The web chat is available Monday to Friday from 6pm to 2am and on Saturday and Sunday from 4pm to 12 midnight. Around 9,500 people are supported by Breathing Space each month, which is typically split between around 95% accessing the helpline and 5% using the web chat function.

The technical issues affecting the Breathing Space web chat function over the last few weeks have now been fully resolved, and NHS24 has assured Scottish Government that if has robust monitoring plans in place to ensure any future issues are identified, and resolved, quickly.

During the period of disruption to the web chat service, the Breathing Space phone lines were unaffected; users were advised via the Breathing Space website that the telephone service remained available. Those with pressing mental health issues also continued to have 24/7 access to the Mental Health Hub through NHS24’s 111 service.

Officials are engaging with NHS National Services Division (NSD) regularly on the national commissioning of this treatment.

An outline application for the commissioning of a national MRI guided Focussed Ultrasound Service was received from NHS Tayside in March 2023. Subsequent correspondence with NHS Tayside indicated the board was supportive in principle in moving forward with the more detailed planning required to develop a formal specification and proposal.

NHS NSD have encouraged the MRgFUS team in NHS Tayside to submit a formal application for national designation of the MRgFUS service in Dundee, supported by the health board’s Executive Leadership Team, for consideration and scrutiny. NSD hopes to receive such an application from NHS Tayside for 2024-25.

We continue to monitor the implementation and effectiveness of the Young Patients Family Fund (YPFF) and keep this under review.

The National Institute for Health and Care Excellence (NICE) is collaborating with the Scottish Medicines Consortium (SMC) on a joint multiple technology appraisal (MTA) of cystic fibrosis (CF) medicines, including Kaftrio®. The NICE recommendations that were published on 3 November are draft and could change following the current consultation period.

Existing patients and new patients who are started on a CF medicine while the MTA is ongoing will continue to have access to the medicine after NICE and the SMC issue their final recommendations, irrespective of the outcome.

In addition, this week the Medicines and Healthcare products Regulatory Agency (MHRA) extended the licence for Kaftrio and Kalydeco to include children aged two to five years old. This extension helps address the unmet needs of younger children with cystic fibrosis.

I refer the member to the answer to question S6W-22728 on 21 November 2023. All answers to written parliamentary questions are available on the Parliament’s website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers .

The total cost of the public inquiry into hepatitis C and HIV infection acquired from NHS treatment in Scotland (the Penrose Inquiry) was £12,123,754. Approximately 42.5% of these costs were spent on legal fees, including legal representation for patients and relatives and other witnesses, and fees for Counsel to the Inquiry. A breakdown of costs is available on the Penrose Inquiry website at Copy of Penrose Inquiry - Publication of Costs .

Due to the nature of the eligibility criteria, the number of households eligible to apply for the scheme varies according to the number of households in receipt of the relevant social security benefits at any given time. However analysis of the eligibility criteria in December 2022 estimated that a total of 208,000 households were eligible to receive support at that time. Analysis of the current eligibility criteria for phase 2 of WHS estimates that around 433,000 households will be eligible.

The following table shows the number of households who have received support each financial year in phase 1 of Warmer Homes Scotland.

The Scottish Medicines Consortium (SMC) continues to provide early information - on an in confidence basis - to Health Boards on medicines in clinical development that are expected to require a companion diagnostic through regular horizon scanning reports.

As part of the Scottish Strategic Network for Genomic Medicine (SSNGM), the Scottish Genomic Testing Advisory Group (SG-TAG) for cancer is now live, and has successfully carried out a review of a new genomic testing pathway for biliary tract cancer which was approved for implementation. This cancer pathway includes diagnostic and prognostic targets, and also targets for SMC approved medicines. The equivalent group for Rare and Inherited Conditions is due to launch next month. Both groups will include a process for considering the laboratory genomics delivery model as well as the cost of the genomic testing pathway for SMC approved medicines.

The Action Plan reflects on the strong evidence of what we know works and builds on the firm foundations of best practice to reduce delayed discharges and overall hospital occupancy and reasserts the Scottish Government’s commitment to responding to the many challenges that still exist over the coming winter.

On 24-hour delays, while we absolutely need to work to reduce these instances, it is important to emphasize that these figures represent a fraction (0.6%) of all attendances to Emergency Departments in this period. The patients experiencing these waits will, in the main, be those who require admission and are waiting for a bed in a ward. They will have been triaged and seen by a doctor.

The Scottish Government is committed to preventing the harm caused by alcohol consumption during pregnancy and to supporting those impacted by Fetal Alcohol Spectrum Disorder (FASD).

We recognise there is more that needs to be done to support people with FASD, that is why we provide funding to the Fetal Alcohol Advisory Support and Training Team (FAASTT) to allow the delivery of training to improve knowledge, attitudes and confidence in professionals working with individuals with FASD.

We also provide funding to the FASD Hub in Scotland with the aim of providing support, training and advice to families, carers and professionals supporting children affected by FASD as well as a new project supporting adults with FASD. This was the first FASD Hub of its kind in the UK.